Prostate Cancer Support Group - Richmond, Va


Meeting Dates - 3rd Thurs. each month - Time 7:00 PM - No July Meeting - The Dec. date will vary - Call for details - Peter C. Moon Phd. at 804-346-4407 between 7 - 11:00 PM - Location - Ridge Baptist Church, 1515 Eastridge Road Richmond, VA 23229

Vet

Rva Prostate Cancer Support Group

www.rvaprostatecancersupport.org
RVA

Advanced Prostate Cancer Page

In good faith, this website was created to furnish you with helpful information. Nevertheless, no one who contributes or posts information to this website makes any guarantee regarding the information provided. Any decisions that you make regarding your health should be made in consultation with a qualified healthcare provider.


Affiliated with Us-TOO International Prostate Cancer Education & Support Network
Home Us Too International Other Support Groups Facts and Stats Emerging Treatments Contact Us Videos Complementary
Alternative Treatment Sources
Links Peter's Notes Flyer

*******************************************************************************************************
Advanced Prostate Cancer

Prostate Cancer
*******************************************************************************************************
AR Targeing in Non-CRPC ---- Can we do beter?

These slides show the many advanced treatments for advanced cancer without talk so you have to study the graphs to decipher what is going on.

Click on Our Link to read more - Non-CRP
or Go To
http://rvaprostatecancersupport.org/PDF/PCa-Ryan Slides-AR Target-Early.pdf
*******************************************************************************************************
Circulating tumor cells(CTC) - which will show the # of these cells in 7.5 ml of blood. If the cells are less than 5 the survival is favorable. So I will check cell numbers now to know for a baseline and after 3 months of treatment to see if the treatment is working by lowering the number of circulating cancer cells. A new treatment is yet to be decided but I expect it to be Casodex. If I see signs of PSA increasing after I have been on treat for a while assuming the treatment works to bring down the PSA as expected, I will get additional CTC test to see what is going on.

Information about the CTC tests can be found at this website:

Click on Our Link to read more
CTC
or Go To
https://www.cellsearchctc.com/about-cellsearch/what-is-cellsearch-ctc-test

*******************************************************************************************************
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
Resistance to second-generation androgen receptor (AR) antagonists and CYP17 inhibitors in patients with castrationresistant prostate cancer (CRPC) develops rapidly through reactivation of the androgen signaling axis and has been attributed to AR overexpression, production of constitutively active AR splice variants, or the selection for AR mutants with altered ligandbinding specificity. It has been established that androgens induce cell-cycle progression, in part, through upregulation of cyclin D1 (CCND1) expression and subsequent activation of cyclin-dependent kinases 4 and 6 (CDK4/6).
Click on Our Link to read more - CDK4
or Go To
http://rvaprostatecancersupport.org/PDF/PCa-CDK4-6 looks better than taxanes if enzalutamide fails Mol Cancer Res-2017-Stice.pdf
*******************************************************************************************************
Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT.
Click on Our Link to read more - Metformin
or Go To
https://www.ncbi.nlm.nih.gov/pubmed/28837141
*******************************************************************************************************
A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer
Click on Our Link to read more - Patches
or Go To
https://www.urotoday.com/clinical-trials/prostate-cancer/93644-a-randomized-controlled-trial-of-transcutaneous-oestrogen-patches-versus-lhrh-agonists-in-prostate-cancer-2.html
********************
ASCO 2017: How Randomized Trials of STAMPEDE Have Influenced Treatment Decisions in the United Kingdom
Click on Our Link to read more - STAMPEDE
or Go To
https://www.urotoday.com/conference-highlights/asco-2017/asco-2017-prostate-cancer/96343-asco-2017-how-randomized-trials-of-stampede-have-influenced-treatment-decisions-in-the-united-kingdom.html
********************
The Local Experience by one of Our Own
(with Ketoconozole and Estrogen patches)
I was diagnosed at age 50 in 1999 with a Gleason of 3+3 and had surgery to remove the prostate.
Click on Our Link to read more - Our Own
or Go To
http://rvaprostatecancersupport.org/Our Own.pdf
*******************************************************************************************************
Article:

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade.
On This Site You will find:

Prostate cancer (PCa) is the most common malignancy among Western men and the second leading-cause
of cancer related deaths. For men who develop metastatic castration resistant PCa (mCRPC), survival is
limited, making the identification of novel therapies for mCRPC critical.

Click on Our Link to read more
Lipid Catabolism
or go to:
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/95534-lipid-catabolism-inhibition-sensitizes-prostate-cancer-cells-to-antiandrogen-blockade.html
*******************************************************************************************************
Article:

Advanced Prostate Cancer Consensus Conference: APCCC
On This Site You will find:

Articles - Video Lectures - Clinical Trials -Centers of Excellence - Conference Highlights - Journal - Calendar

Click on Our Link to read more
Conference
or go to:
https://www.urotoday.com/video-lectures/advanced-prostate-cancer-consensus-conference-apccc.html?utm_source=newsletter_4444&utm_medium=email&utm_campaign=advanced-prostate-cancer-consensus-conference-interviews-with-presenters-by-alicia-morgans-neal-shore-and-charles-ryan
*******************************************************************************************************
Article:

PCa Commentary Vol. #105: FOLLICLE STIMULATING HORMONE (FSH): Its Suppression by Degarelix (Firmagon)
May Contribute to the Drug’s Effectiveness in Androgen Suppression and Its Lesser Cardiotoxicity Compared to Leuprolide (Lupron.)

FOLLICLE STIMULATING HORMONE
or go to:
http://www.pctrf.org/pca-commentary-vol-105-follicle-stimulating-hormone-fsh-suppression-degarelix-firmagon-may-contribute-drugs-effectiveness-androgen-suppression-lesser-cardioto/
*******************************************************************************************************
Article:

Clinical comparison of the efficacy of three different bowel preparation methods on the infectious
complications following transrectal ultrasonography guided prostate biopsy in nursing practice.

Click on Our Link to read more
Infection
or go to:
https://www.ncbi.nlm.nih.gov/pubmed/28401738
*******************************************************************************************************
Article:

Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy
(SBRT) for early-stage prostate cancer.

Click on Our Link to read more
CyberKnife
or go to:
https://www.ncbi.nlm.nih.gov/pubmed/28407345
*******************************************************************************************************
PAN Foundation

The copay assistance program for individuals with metastatic prostate cancer has just opened at the Patient
Access Network (PAN) Foundation. This is a great potential opportunity for eligible men affected by metastatic
prostate cancer to receive up to $12,000 a year in financial assistance.

For more information visit:

Click on Our Link to read more

PAN

or go to:
http://bit.ly/2n1SftA

You may apply online or call 1-866-316-7263.

****************************************************************************************************